PRODUCTS / DURASERT™ / LATANOPROST
Glaucoma / DURASERT™ / LATANOPROST
Durasert for glaucoma is a fully bioerodible, long-term, sustained release implant delivering latanoprost, the most commonly prescribed agent for ocular hypertension and glaucoma in the world. The product is designed to be administered by an eye care professional into the subconjunctival space of the eye in a minimally invasive procedure.
A Phase I/II clinical trial designed to assess the safety and efficacy of the implant is underway in patients with elevated intraocular pressure. If successful, we plan to advance the product into a multi-center Phase II clinical trial.
The Durasert/latanoprost program is being developed with Pfizer Inc. pursuant to the Collaborative Research and License Agreement between the two companies.